


Psychopharmacology at the End of Life

Nicole Thurston, MD

Psychiatrist

Mountain States Tumor Institute



Objectives

- Describe 2 common psychiatric symptoms that can present at or near end of life.
- Review the differential diagnoses for end of life psychiatric symptoms.
- Discuss the pros and cons of 3 medications used in specific end of life symptoms



CASE #1: 79 yo man with metastatic pancreatic cancer

- ▣ Referral for: "sadness" and low energy
- ▣ Nonresectable tumor, attempting chemotherapy with gemcitabine, nausea
- ▣ Current symptoms: sadness, lack of enjoyment, hopeless, helpless, anxiety, poor energy, insomnia, no suicidal ideation, no psychosis
- ▣ Other medical conditions: hypertension, hypercholesterolemia, obesity, chronic back pain
- ▣ Current meds: oxycodone SR, oxycodone, prochlorperazine, lorazepam, ondansetron, atorvastatin, atenolol

Considerations?

- ▣ Previous history of psychiatric issues? Previous treatment?
- ▣ Time course of symptoms?
- ▣ Abusing narcotics? Abusing lorazepam?
- ▣ Psychosocial issues?
- ▣ Prognostic awareness?
- ▣ Poor pain control? Nausea control?

Differential diagnosis

- ▣ Adjustment disorder with depression
- ▣ Major depressive disorder
- ▣ Depression secondary to alcohol dependence
- ▣ Depression secondary to narcotic dependence
- ▣ Depression secondary to pain
- ▣ Bereavement

Case #1: Treatment Considerations

- ▣ ALWAYS make sure medical treatments are optimized
 - ▣ Pain control (consider longer acting options if addiction is concern)
 - ▣ Nausea control
- ▣ Traditional antidepressant options
- ▣ Atypical antipsychotic?
- ▣ Stimulant?
- ▣ Future possibilities?

Mirtazapine (Remeron)

- ❑ Alpha-2 antagonist; disinhibits serotonin and norepinephrine release
- ❑ FDA Indications: Major depressive disorder
- ❑ Dosage: 15-45 mg qhs
- ❑ Blocks H1 → weight gain, sedation, drowsiness
- ❑ Blocks several serotonin receptors
 - ❑ 5HT1A → anxiolytic, antidepressant
 - ❑ 5HT2A → anxiolytic, antidepressant, no sexual dysfunction
 - ❑ 5HT2C → anxiolytic, weight gain
 - ❑ 5HT3 → no GI problems, no nausea

Olanzapine (Zyprexa)

- ❑ Serotonin/Dopamine Antagonist
- ❑ FDA Indications: schizophrenia, bipolar disorder, major depressive disorder, tx resistant
- ❑ Off label: mood symptoms, agitation, delirium, nausea
- ❑ Dosage: 2.5-30 mg po qhs
- ❑ Less extrapyramidal symptoms
- ❑ Antiemetic properties (5HT3)
- ❑ Weight gain (5HT2C, H1)

Methylphenidate (Ritalin)

- ❑ Release dopamine from presynaptic terminals
- ❑ FDA Indications: ADHD, narcolepsy
- ❑ Off label: narcotic induced confusion, chemotherapy induced fatigue
- ❑ Dosage: 5-15 mg bid-tid
- ❑ Improve concentration, apathy, mood and energy
- ❑ Benefits: fast acting for energy, mood if effective
- ❑ Side effects: jitteriness, appetite suppression, psychosis (rare)

Ketamine

- ❑ NMDA receptor antagonist
- ❑ FDA Indications: general anesthesia induction and maintenance
- ❑ Off label: May possibly rapidly improve mood in palliative care patients with single oral dosage
- ❑ Dosage:
- ❑ Side effects: delirium, hallucinations, dissociation



Case #2: 55 yo woman with stage IV lung cancer

- ▣ Referral for "anxiety"
- ▣ Primary lung lesion with known metastases to brain, not currently on chemotherapy, on observation but no referral to hospice yet
- ▣ Current symptoms: restless, agitation, pacing, intermittent confusion, mood lability, jerking movements in extremities
- ▣ Other medical conditions: atrial fibrillation, hypothyroidism, COPD, fibromyalgia
- ▣ Current meds: fentanyl, oxycodone, lorazepam, levothyroxine, digoxin, duloxetine, amitriptyline

Considerations?

- ▣ Thyroid status?
- ▣ Digoxin level?
- ▣ Pain control?
- ▣ Psychiatric history?
- ▣ Pattern of benzodiazepine usage? Narcotic usage?
- ▣ Serotonin syndrome?

Differential diagnosis

- ▣ DELIRIUM!
- ▣ Drugs e.g. alcohol, opiates, anticonvulsants, recreational, post-general anesthetic
- ▣ Electrolyte imbalance e.g. hypoglycemia, uremia, liver failure, hypo/hyponatremia
- ▣ Lacking medication/drugs e.g. alcohol withdrawal, benzodiazepine withdrawal
- ▣ Infections e.g. encephalitis, meningitis
- ▣ Reduced sensory input e.g. lack of sleep
- ▣ Intracranial e.g. trauma, strokes
- ▣ Urinary/fecal retention
- ▣ Myocardial (MI) or pulmonary (pneumonia)

Serotonin syndrome

- ❑ Symptoms: Agitation or restlessness, confusion, rapid heart rate, high blood pressure, twitching muscles, heavy sweating, diarrhea, dilated pupils, headache, shivering, goose bumps
- ❑ If severe: irregular heart rate, high fever, seizures, unconsciousness
- ❑ Rule out: alcohol withdrawal, thyroid conditions, anticholinergic syndrome (amitriptyline level), neuroleptic malignant syndrome, amphetamine usage
- ❑ Treatment: stop serotonergic medications, supportive care, cyproheptadine

Cyproheptadine (Periactin)

- ❑ Antagonizes central and peripheral histamine H1 receptors, serotonin receptor antagonist
- ❑ FDA Indications: allergic rhinitis, urticaria, anorexia nervosa
- ❑ Off label: serotonin syndrome
- ❑ Dosage: 4-8 mg bid

Case #2: Treatment considerations

- ❑ Treat medical conditions first!
- ❑ Minimize sedating medications
- ❑ Opioid rotation if concern for opioid induced neurotoxicity
- ❑ If concern for serotonin syndrome stop all serotonergic medications
- ❑ If no medical etiology found consider treating delirium with antipsychotics

Haloperidol (Haldol)

- ❑ Conventional antipsychotic blocks D2 and alpha 1
- ❑ FDA Indications: psychosis, tourette syndrome, acute agitation
- ❑ Dosage: 2 mg po q6h with 2 mg po q1h prn or 1mg IV q6h and 1mg IV q1h prn
- ❑ Lacks potent antimuscarinic and antihistaminic activity
- ❑ Side effects: decreased blood pressure, dizziness, drowsiness, QTc prolongation (check baseline EKG)

Bottom Line

- ❑ Medically complex
- ❑ Polypharmacy issues are the norm; try to simplify if at possible and use medications with multiple actions
- ❑ Team approach (oncologist, palliative medicine, primary care, psychiatrist, pharmacist) and communication is key



References

- ❑ Scott A Irwin, MD, PhD and Alana Iglewicz, MD. "Oral Ketamine for the Rapid Treatment of Depression and Anxiety in Patients Receiving Hospice Care". *J Palliat Med*. 2010 July; 13(7): 903-908.
- ❑ Stephen M. Stahl. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed.
- ❑ Epocrates
- ❑ Wikipedia (Van Gogh)